These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 18512184)

  • 21. Dimethyltryptamine (DMT): prevalence, user characteristics and abuse liability in a large global sample.
    Winstock AR; Kaar S; Borschmann R
    J Psychopharmacol; 2014 Jan; 28(1):49-54. PubMed ID: 24284475
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The hallucinogens and the inhalants.
    Cohen S
    Psychiatr Clin North Am; 1984 Dec; 7(4):681-8. PubMed ID: 6097885
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacologic Similarities and Differences Among Hallucinogens.
    Waters K
    J Clin Pharmacol; 2021 Aug; 61 Suppl 2():S100-S113. PubMed ID: 34396556
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Hallucinogen induced psychic disorders. Subjective experiences, psychopathology and differential diagnosis].
    Hermle L; Gouzoulis-Mayfrank E; Spitzer M
    Fortschr Neurol Psychiatr; 1996 Dec; 64(12):482-91. PubMed ID: 9053389
    [TBL] [Abstract][Full Text] [Related]  

  • 25. LSD-associated "Alice in Wonderland Syndrome"(AIWS): A Hallucinogen Persisting Perception Disorder (HPPD) Case Report.
    G Lerner A; Lev-Ran S
    Isr J Psychiatry Relat Sci; 2015; 52(1):67-8. PubMed ID: 25841113
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): a double-blind, cross-over study in healthy volunteers.
    Gouzoulis-Mayfrank E; Heekeren K; Neukirch A; Stoll M; Stock C; Obradovic M; Kovar KA
    Pharmacopsychiatry; 2005 Nov; 38(6):301-11. PubMed ID: 16342002
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hallucinogen persisting perception disorder after psilocybin consumption: a case study.
    Espiard ML; Lecardeur L; Abadie P; Halbecq I; Dollfus S
    Eur Psychiatry; 2005 Aug; 20(5-6):458-60. PubMed ID: 15963699
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Abnormal visual experiences in individuals with histories of hallucinogen use: a Web-based questionnaire.
    Baggott MJ; Coyle JR; Erowid E; Erowid F; Robertson LC
    Drug Alcohol Depend; 2011 Mar; 114(1):61-7. PubMed ID: 21035275
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hallucinogen-Induced Persisting Perception Disorder: A Case Report.
    Ayyub J; Nandennagari S; Edelbaum D; Agbo J; Nagendran D; Tamayo L
    Cureus; 2023 Sep; 15(9):e46262. PubMed ID: 37908914
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hallucinogen Use and Misuse in Older Adults.
    Redden WM; Paracha SU; Sheheryar Q
    Clin Geriatr Med; 2022 Feb; 38(1):55-66. PubMed ID: 34794703
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Schizophrenia and hallucinogen persisting perception disorder: A clinical investigation.
    Lev-Ran S; Feingold D; Rudinski D; Katz S; Arturo LG
    Am J Addict; 2015 Apr; 24(3):197-199. PubMed ID: 25808913
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The "Endless Trip" among the NPS Users: Psychopathology and Psychopharmacology in the Hallucinogen-Persisting Perception Disorder. A Systematic Review.
    Orsolini L; Papanti GD; De Berardis D; Guirguis A; Corkery JM; Schifano F
    Front Psychiatry; 2017; 8():240. PubMed ID: 29209235
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Psychedelics and Hallucinogens in Psychiatry: Finding New Pharmacological Targets.
    Sousa TR; Rema J; Machado S; Novais F
    Curr Top Med Chem; 2022; 22(15):1250-1260. PubMed ID: 34852736
    [TBL] [Abstract][Full Text] [Related]  

  • 34. To treat or not to treat? High-potency benzodiazepine use in a case of comorbid hallucinogen persisting perception disorder and alcohol use disorder.
    Christensen JA; Fipps DC; Bostwick JM
    Exp Clin Psychopharmacol; 2023 Apr; 31(2):300-304. PubMed ID: 36048112
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Who takes the trip? Personality and hallucinogen use among college students and adolescents.
    Parnes JE; Kentopp SD; Conner BT; Rebecca RA
    Drug Alcohol Depend; 2020 Dec; 217():108263. PubMed ID: 32932162
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Psilocybin--summary of knowledge and new perspectives.
    Tylš F; Páleníček T; Horáček J
    Eur Neuropsychopharmacol; 2014 Mar; 24(3):342-56. PubMed ID: 24444771
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A comparison of the phenomenology of hallucinogens and schizophrenia from some autobiographical accounts.
    Kleinman JE; Gillin JC; Wyatt RJ
    Schizophr Bull; 1977; 3(4):560-86. PubMed ID: 271353
    [No Abstract]   [Full Text] [Related]  

  • 38. Hallucinogen Persisting Perception Disorder and Risk of Suicide.
    Brodrick J; Mitchell BG
    J Pharm Pract; 2016 Aug; 29(4):431-4. PubMed ID: 25631475
    [TBL] [Abstract][Full Text] [Related]  

  • 39. LSD-induced Hallucinogen Persisting Perception Disorder with depressive features treated with reboxetine: case report.
    Lerner AG; Shufman E; Kodesh A; Kretzmer G; Sigal M
    Isr J Psychiatry Relat Sci; 2002; 39(2):100-3. PubMed ID: 12227224
    [TBL] [Abstract][Full Text] [Related]  

  • 40. LSD-induced hallucinogen persisting perception disorder treatment with clonidine: an open pilot study.
    Lerner AG; Gelkopf M; Oyffe I; Finkel B; Katz S; Sigal M; Weizman A
    Int Clin Psychopharmacol; 2000 Jan; 15(1):35-7. PubMed ID: 10836284
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.